Our previous investigation based on network pharmacology revealed that SGKL targets the PI3K/Akt/mTOR pathway, indicating that SGKL might contribute to alleviating depression symptoms through the PI3K/Akt/mTOR pathway. This evidence concerns the gene SGK3 and depressive symptom measurement.